Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia

Table 1 Summary of level (depth) of molecular response required prior to discontinuation attempt in discontinuation clinical trials, for all of these studies, molecular relapse was considered to be loss of major molecular response

Molecular response	Trial	TKI	TFR, %	TFR at month
MMR	Destiny	Dasatinib	39	24
DMR	JALSG-STIM213	Imatinib	68	12
DMR	DASFREE	Dasatinib	63	12
DMR	ENESTFreedom	Nilotinib	52	12
DMR	ENESTop	Nilotinib	58	12
DMR	EURO-SKI	Mixed	61	6
CMR1	STIM12	Imatinib	43	6
UMRD	ISAV3	Imatinib	48	36
UMRD	STOP 2G-TKI4	Mixed	61	12
UMRD	STIM25	Imatinib	64	6
UMRD	KIDS6	Imatinib	62	12
UMRD	TWISTER6	Imatinib	47	24

¹Complete molecular response should not be detectable but could be MR⁴ or MR^4.5 depending on the sensitivity of the BCR-ABL1 transcript quantification technique used[63].

²> 5-log reduction.

³Limit of detection log4-4.5.

⁴Undetectable BCR-ABL1 by real-time quantitative polymerase chain reaction, with at least 20,000 copies of the control gene.

⁵Undetectable BCR-ABL1 with sensitivity ≥ 50000 amplified copies of ABL1 control gene.

⁶Limit of detection log4.5. CMR: Complete molecular response; DMR: Deep molecular response MR⁴ or better (< 0.01%); MMR: Major molecular response, MR³ (0.1%); TFR: Treatment free remission; TKI: Tyrosine kinase inhibitor; UMRD: Undetectable molecular residual disease.